| Airway clearance# | Inhaled corticosteroids# | rhDNase¶ | Antibiotics for exacerbations# | Prophylactic antibiotics#+ | |||||||||||
| OR | 95% CI | p-value | OR | 95% CI | p-value | OR | 95% CI | p-value | OR | 95% CI | p-value | OR | 95% CI | p-value | |
| PCD patients cared for n | |||||||||||||||
| 0–2 | 1 | 0.032 | 1.00 | 0.025 | 1.00 | 0.032 | 1.00 | 0.092 | 1.00 | 0.333 | |||||
| 3–5 | 1.7 | 0.7–4.0 | 0.4 | 0.1–1.2 | 1.6 | 0.7–3.6 | 2.8 | 0.8–9.5 | 1.9 | 0.8–4.5 | |||||
| ≥6 | 3.2 | 1.3–7.7 | 0.3 | 0.1–0.9 | 2.6 | 1.3–5.4 | 2.7 | 0.9–7.8 | 1.3 | 0.6–2.9 | |||||
| European region | |||||||||||||||
| Western | 1 | 0.302 | 1.00 | 0.063 | 1.00 | 0.326 | 1.00 | 0.215 | 1.00 | 0.063 | |||||
| British Isles | 1.4 | 0.4–4.5 | 0.7 | 0.1–3.6 | 1.4 | 0.6–3.3 | 0.8 | 0.2–3.3 | 2.5 | 01.0–6.3 | |||||
| Southern | 0.7 | 0.3–1.9 | 3.5 | 1.1–11.2 | 0.7 | 0.3–1.5 | 0.7 | 0.2–2.5 | 0.6 | 0.2–1.6 | |||||
| Northern | 0.7 | 0.2–2.4 | 5.1 | 1.4–18.7 | 0.8 | 0.3–2.3 | 0.3 | 0.1–1.1 | 1.5 | 0.5–4.6 | |||||
| Eastern | 0.4 | 0.1–1.1 | 1.4 | 0.3–6.4 | 0.5 | 0.2–1.2 | 2.9 | 0.3–26.0 | 1.8 | 0.7–4.78 | |||||
Results are adjusted for size of centre (number of PCD children) and region. European regions are defined as follows. Western Europe: Austria, Belgium, France, Germany, the Netherlands and Switzerland (n=61); British Isles: Ireland and UK (n=33); southern Europe: Cyprus, Greece, Italy, Portugal and Spain (n=47); northern Europe: Denmark, Finland, Norway and Sweden (n=22); eastern Europe: Bulgaria, Czech Republic, Estonia, Hungary, Israel, Romania, Serbia, Slovakia and Turkey (n=31) (total n=194). OR: odds ratio; CI: confidence interval. #: routinely used (for all children); ¶: frequently or sometimes used (for some children); +: prophylactic nebulised antibiotics, prophylactic oral antibiotics, intermittent oral antibiotics, regular intravenous antibiotics or intermittent intravenous antibiotics.